A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML

This study looks at whether patients with chronic myeloid leukemia (CML) can safely stop their medication after gradually reducing the dose. Patients who have been on second-generation tyrosine kinase inhibitors (nilotinib or dasatinib) for at least 3 years and have maintained a deep molecular response for at least 2 years will try taking a half dose for 12 months, then stopping completely for another 12 months. Adults (18+) diagnosed with CML who meet the response criteria are eligible, though those with certain heart conditions, prior stem cell transplants, or severe organ problems are excluded. Participation involves regular blood tests every 1–3 months to monitor whether the leukemia remains under control, with the original dose restarted if the disease comes back. This summary was prepared using AI to help patients understand the study in plain language.